tradingkey.logo

BRIEF-Pliant Therapeutics Provides Update On Beacon-IPF

ReutersMar 3, 2025 2:50 PM

- Pliant Therapeutics Inc PLRX.O:

  • PLIANT THERAPEUTICS PROVIDES UPDATE ON BEACON-IPF, A PHASE 2B/3 TRIAL IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

  • PLIANT THERAPEUTICS INC - DISCONTINUES BEACON-IPF PHASE 2B TRIAL

  • PLIANT THERAPEUTICS INC - TRIAL DISCONTINUED DUE TO IPF-RELATED ADVERSE EVENTS

  • PLIANT THERAPEUTICS INC - COMMITTED TO DEVELOPMENT OF OTHER CLINICAL ASSETS INCLUDING PLN-101095 IN ONCOLOGY

  • PLIANT THERAPEUTICS INC: EARLY EVIDENCE OF EFFICACY ON FORCED VITAL CAPACITY (FVC) ENDPOINT WAS ALSO OBSERVED IN BEACON-IPF TRIAL

Source text: ID:nGNX2pcbQM

Further company coverage: PLRX.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI